Making the discoveries that defeat cancer

  • Home »
  • Research »
  • Repository

  • Administrators Login

  • Repository Homepage
  • About the Repository
  • Browse the Repository
  • Search the Repository
  • Contribute an Article
  • Missing Publications
  • Repository Help

Emerging Technologies for Assessing HER2 Amplification

Tools
- Tools
+ Tools

Penault-Llorca, F., Bilous, M., Dowsett, M., Hanna, W., Osamura, R. Y., Rueschoff, J., van de Vijver, M. (2009) Emerging Technologies for Assessing HER2 Amplification. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 132 (4). pp. 539-548. ISSN 0002-9173

Full text not available from this repository.

Abstract

Patients with human epidermal growth factor receptor-2 (HER2)+ breast cancer are eligible for trastuzumab treatment: therefore, accurate assessment of HER2 status is essential. Until recently, only 2 methods were validated for determining the HER2 status of breast tumors in the routine diagnostic selling: immunohistochemical analysis and fluorescence in situ hybridization (FISH). Recently bright-field in situ hybridization techniques such as chromogenic in situ hybridization (CISH) and silver-enhanced in situ hybridization (SISH), which combine features of immunohistochemical analysis and FISH, have been introduced for the determination of HER2 status. These new techniques use a peroxidase enzyme-labeled probe with chromogenic defection, instead of fluorescent-labeled probe, allowing results to be visualized by standard bright-field microscopy. Thus, the histologic features and HER2 status of a specimen can be evaluated in parallel. Moreover, signals do not decay over time. This review discusses recent publications regarding CISH and SISH testing, including results scoring and concordance between FISH and immunohistochemical analysis.

Item Type: Review Article
Authors (ICR Faculty only): Dowsett, Mitch
All Authors: Penault-Llorca, F., Bilous, M., Dowsett, M., Hanna, W., Osamura, R. Y., Rueschoff, J., van de Vijver, M.
Uncontrolled Keywords: HER2; Breast cancer; Immunohistochemical analysis; Chromogenic in situ hybridization; CISH; Fluorescence in situ hybridization; FISH;IN-SITU HYBRIDIZATION; METASTATIC BREAST-CANCER; HER-2/NEU GENE AMPLIFICATION; ONCOGENE AMPLIFICATION; ADJUVANT CHEMOTHERAPY; MONOCLONAL-ANTIBODY; TISSUE MICROARRAYS; 1ST-LINE TREATMENT; FOLLOW-UP; FLUORESCENCE
Research teams: ICR divisions > Breast Cancer Research > Endocrinology
ICR divisions > Molecular Pathology > Endocrinology
Depositing User: Users 10 not found.
Date Deposited: 26 Oct 2009 10:33
Last Modified: 10 Feb 2014 16:28
URI: http://publications.icr.ac.uk/id/eprint/8879

Actions (login required)

View Item View Item
The Royal Marsden - NHS foundation trust